---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-140285"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2025-06-13T23:59:59+00:00"
generated_at: "2026-05-19T08:31:18.724581+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Enliven reports 47% cumulative MMR by 24 weeks for ELVN-001 in Phase 1 CML trial; well-tolerated

## Summary
- 47% of evaluable patients (25/53) achieved MMR by 24 weeks; 32% (13/41) achieved MMR, comparing favorably to asciminib's 24% in Phase 1.
- 90 patients enrolled; 80% remain on study with median treatment duration ~29 weeks; heavily pretreated (67% received ≥3 prior TKIs).
- Safety: only 3.4% dose reductions, 4.6% discontinuations due to AEs; no treatment-related arterial occlusive events; no MTD reached.
- PK supports once-daily dosing with food flexibility and low drug-drug interaction potential.
- Company expects to initiate first head-to-head Phase 3 pivotal trial in 2026.

## SEC filing metadata
- accession: 0001193125-25-140285
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2025-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312525140285/0001193125-25-140285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312525140285/d877944d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-140285
- JSON: https://secwatch.observer/filing/0001193125-25-140285.json
- Plain text: https://secwatch.observer/filing/0001193125-25-140285.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.